3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Renal Cell
11
Prostatic Neoplasms
3
Neoplasms
3
Kidney Neoplasms
3
Carcinoma
3
Pain
2
Clear-cell metastatic renal cell carcinoma
2
Carcinoma, Medullary
2
Carcinoma, Hepatocellular
2
von Hippel-Lindau Disease
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid cancer, follicular
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Lymphatic Metastasis
1
Liver Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenoma, Islet Cell
1
Adenocarcinoma, Follicular
1
Interventions
Sorafenib
8
durvalumab
4
Cisplatin
4
Gemcitabine
3
Ethiodized Oil
3
Doxorubicin
3
Chemotherapy, Adjuvant
3
Bevacizumab
3
tremelimumab
2
sodium thiosulfate
2
phosphomannopentaose sulfate
2
Watchful Waiting
2
Talaporfin
2
Radiofrequency Ablation
2
Oxaliplatin
2
Nivolumab
2
Folfox protocol
2
Celecoxib
2
Capecitabine
2
Analgesia, Patient-Controlled
2
seocalcitol
1
parecoxib
1
nolatrexed
1
linifanib
1
lenvatinib
1
ferumoxides
1
ferric carboxymaltose
1
contrast agent BR1
1
cabozantinib
1
brivanib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Liver Neoplasms
×
cabozantinib
×
Clear all
NCT01908426
2021-05-06
CELESTIAL
Exelixis
Phase 3
Completed
707 enrolled
20 charts
1 FDA